This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
FNIH has selected CRI to be its source of landscape intelligence in immuno-oncology.
Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.
A comprehensive, neutral analysis of the global cancer cell therapy landscape; 753 cancer cell therapies in the global development pipeline, with 375 in clinical studies
30 days of education and awareness programming for patients, caregivers, and the public about cancer immunotherapy and clinical trials
Cancer Research Institute iAtlas Poised to Improve Patient Outcomes by Providing Researchers Greater Access to Genomics Data
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Combined with chemotherapy, an HPV-targeting vaccine developed by CRI scientists led to encouraging responses in women with advanced cervical cancer.
Lessons learned from cancer immunotherapy research may help to curb the COVID-19 pandemic.